Business Wire

NC-LENOVO

8.9.2021 06:02:11 CEST | Business Wire | Press release

Share
Lenovo Launches Global Everything-as-a-Service Strategy

Today, at its annual Tech World event, Lenovo announced an evolution in its consumption-based business model, introducing Lenovo TruScale , a new portfolio-spanning everything-as-a-service offering. This announcement is part of Lenovo’s continuing transformation for the next reality – a new era where consumers and business leaders need new solutions and technologies to face unprecedented change in business, education, living and beyond.

Expanding its TruScale brand beyond infrastructure services, Lenovo is bringing all of its as-a-service offerings under one umbrella to provide a truly global solution that makes everything from the pocket to the cloud available via a single contract framework. Lenovo TruScale embodies the company’s vision and transformation for the next reality – meeting the growing global demand for smarter technology amid a new era of hybrid working and learning.

“Digital transformation is accelerating faster than ever, and companies are struggling to keep pace with the speed of innovation. We hear from CIOs every day that their organizations’ technology needs are evolving every 12-18 months,” said Ken Wong, president of Solutions & Services Group. “With Lenovo TruScale, customers can expect one solution, one provider, one contract framework, and a single point of accountability for everything-as-a-service.”

Lenovo TruScale offers businesses of all sizes an everything-as-a-service platform with the flexibility they need to stay competitive with a scalable, cloud-like consumption model and predictable payment options for hardware and service inclusions. This transition to a fully integrated as-a-service strategy brings to life the company’s “One Lenovo” vision – addressing common business challenges and providing IT leaders with the performance and flexibility to pay-as-you-grow. With Lenovo TruScale, IT leaders’ infrastructure solutions are fully managed, giving customers the advantages of an on-premise cloud environment along with the peace of mind around data management in a hybrid environment.

Research shows the as-a-service market is growing at four times the overall IT services total addressable market. In three years, as-a-service models will represent 12% of enterprise x86 server spend and over 50% of new enterprise storage spend, growing at 40% CAGR and around 17% of commercial PC spend, up from 1% two years ago and growing at 50% CAGR.1

As the world shifts to a flexible “work, learn and connect-from-anywhere” model, organizations that embrace smarter technology designed for a hybrid reality will benefit from this transition. This requires flexibility in devices and work platforms, on-demand support when and where needed, and customizable solutions across the organization, benefits that many will recognize from Lenovo’s existing Device-as-a-Service solution. Now moving under the new TruScale umbrella, Lenovo DaaS will continue to help customers move to a Modern IT environment by combining the best end-to-end technology from across Lenovo with lifecycle services and support and convenient financing to deliver lower total cost of ownership.

Lenovo is building a new way to deliver as-a-service to the market and offer organizations ultimate flexibility in how they leverage their IT infrastructure, services and software. By forming strategic alliances with other market leaders, customers can get the public cloud experience with the security and control of an on-premises solution. As part of this new platform, Lenovo has joined with leading infrastructure partners Deloitte, VMWare and Intel, and DaaS security partners Absolute Software and SentinelOne to provide organizations with various dynamic offerings such as hybrid cloud solutions for Edge to Cloud environments, best-in-class managed security solutions and access to the most current storage infrastructure innovation, for the life of their data, with the ability to scale storage capacity on demand.

“Lenovo’s as-a-service approach helps meet the market's demand for responsive, reliable hybrid cloud operations. Put simply our organizations are helping companies grow their enterprises and mitigate risks to create more value and serve society better,” said Punit Renjen, CEO of Deloitte Global.

Learn more about TruScale’s latest offerings at Lenovo’s annual global innovation event, Tech World .

1 Gartner, IDC, Lenovo Market Intelligence

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye